Phase Behavior of Poly(vinylpyrrolidone) Containing Amorphous Solid Dispersions in the Presence of Moisture

The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analys...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics Vol. 6; no. 5; pp. 1492 - 1505
Main Authors: Rumondor, Alfred C. F, Marsac, Patrick J, Stanford, Lindsay A, Taylor, Lynne S
Format: Journal Article
Language:English
Published: United States American Chemical Society 05-10-2009
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine−poly(vinylpyrrolidone) (PVP), indomethacin−PVP, ketoprofen−PVP, droperidol−PVP, and pimozide−PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug−polymer interactions and a single glass transition (T g) event. Following storage at elevated relative humidity (75−94% RH), nifedipine−PVP, droperidol−PVP, and pimozide−PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin−PVP and ketoprofen−PVP dispersions did not. Drug crystallization in systems exhibiting amorphous−amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (≥46 days at 94% RH). Evidence of moisture-induced amorphous−amorphous phase separation was observed following storage at as low as 54% RH for the pimozide−PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous−amorphous phase separation. The strength of drug−polymer interactions appears to be important in influencing the phase behavior.
AbstractList The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine-poly(vinylpyrrolidone) (PVP), indomethacin-PVP, ketoprofen-PVP, droperidol-PVP, and pimozide-PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug-polymer interactions and a single glass transition (T(g)) event. Following storage at elevated relative humidity (75-94% RH), nifedipine-PVP, droperidol-PVP, and pimozide-PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin-PVP and ketoprofen-PVP dispersions did not. Drug crystallization in systems exhibiting amorphous-amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (>or=46 days at 94% RH). Evidence of moisture-induced amorphous-amorphous phase separation was observed following storage at as low as 54% RH for the pimozide-PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous-amorphous phase separation. The strength of drug-polymer interactions appears to be important in influencing the phase behavior.
The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer following exposure to elevated relative humidity. Infrared (IR) spectroscopy, differential scanning calorimetry (DSC) and moisture sorption analysis were performed on five model systems (nifedipine−poly(vinylpyrrolidone) (PVP), indomethacin−PVP, ketoprofen−PVP, droperidol−PVP, and pimozide−PVP) immediately after production of the amorphous solid dispersions and following storage at room temperature and elevated relative humidity. Complete miscibility between the drug and the polymer immediately after solid dispersion formation was confirmed by the presence of specific drug−polymer interactions and a single glass transition (T g) event. Following storage at elevated relative humidity (75−94% RH), nifedipine−PVP, droperidol−PVP, and pimozide−PVP dispersions formed drug-rich and polymer-rich amorphous phases prior to crystallization of the drug, while indomethacin−PVP and ketoprofen−PVP dispersions did not. Drug crystallization in systems exhibiting amorphous−amorphous phase separation initiated earlier (<6 days at 94% RH) when compared to systems that remained miscible (≥46 days at 94% RH). Evidence of moisture-induced amorphous−amorphous phase separation was observed following storage at as low as 54% RH for the pimozide−PVP system. It was concluded that, when an amorphous molecular level solid dispersion containing a hydrophobic drug and hydrophilic polymer is subjected to moisture, drug crystallization can occur via one of two routes: crystallization from the plasticized one-phase solid dispersion, or crystallization from a plasticized drug-rich amorphous phase in a two-phase solid dispersion. In the former case, the polymer is still present in the same phase as the drug, and can inhibit crystallization to a greater extent than the latter scenario, where the polymer concentration in the drug phase is reduced as a result of the amorphous−amorphous phase separation. The strength of drug−polymer interactions appears to be important in influencing the phase behavior.
Author Taylor, Lynne S
Stanford, Lindsay A
Marsac, Patrick J
Rumondor, Alfred C. F
Author_xml – sequence: 1
  givenname: Alfred C. F
  surname: Rumondor
  fullname: Rumondor, Alfred C. F
– sequence: 2
  givenname: Patrick J
  surname: Marsac
  fullname: Marsac, Patrick J
– sequence: 3
  givenname: Lindsay A
  surname: Stanford
  fullname: Stanford, Lindsay A
– sequence: 4
  givenname: Lynne S
  surname: Taylor
  fullname: Taylor, Lynne S
  email: ltaylor@pharmacy.purdue.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19634917$$D View this record in MEDLINE/PubMed
BookMark eNptkEtPwzAQhC1URB9w4A8gX5DoIWDHcRIfS3lKRVQCzpHj2MQlsSM7qZR_T6pW5cJpVtpPszszBSNjjQTgEqNbjEJ8VzcMIUSROAETTCMSpISFo-OcRmMw9X6DUBjRkJyBMWYxiRhOJuBnXXIv4b0s-VZbB62Ca1v1N1tt-qrpnbOVLoZrc7i0puXaaPMNF7V1TWk7Dz92a_igfSOd19Z4qA1sSwnXTnpphNwZvlnt287Jc3CqeOXlxUFn4Ovp8XP5Eqzen1-Xi1XASYragDKVsoTEhRgUD7mYyhVRJGEiiRGLCprmqlC5SDESRPKcSFXIKI8pprGIKZmB-d5XOOu9kyprnK656zOMsl1h2bGwgb3as02X17L4Iw8NDcD1HuDCZxvbOTO8_o_RL3pFdbw
CitedBy_id crossref_primary_10_1016_j_ijpharm_2013_07_030
crossref_primary_10_1021_acs_cgd_6b01901
crossref_primary_10_1146_annurev_chembioeng_060718_030304
crossref_primary_10_1002_jps_22247
crossref_primary_10_1021_acs_molpharmaceut_6b00866
crossref_primary_10_1021_mp300423r
crossref_primary_10_3390_polym13172922
crossref_primary_10_1007_s12247_012_9121_2
crossref_primary_10_1016_j_matpr_2019_03_171
crossref_primary_10_1016_j_xphs_2016_06_017
crossref_primary_10_1021_mp300079x
crossref_primary_10_1016_j_xphs_2021_10_016
crossref_primary_10_1080_17425247_2016_1198769
crossref_primary_10_1002_jps_24261
crossref_primary_10_1021_acs_molpharmaceut_6b01151
crossref_primary_10_1016_j_ejps_2019_105057
crossref_primary_10_1016_j_xphs_2022_09_013
crossref_primary_10_1021_acs_molpharmaceut_5b00925
crossref_primary_10_1007_s11095_022_03183_4
crossref_primary_10_1021_acs_molpharmaceut_9b01272
crossref_primary_10_1016_j_ijpharm_2023_123490
crossref_primary_10_1016_j_xphs_2020_09_016
crossref_primary_10_1007_s11095_012_0689_5
crossref_primary_10_1016_j_xphs_2018_02_008
crossref_primary_10_1021_acs_molpharmaceut_1c00972
crossref_primary_10_3109_10837450_2013_775157
crossref_primary_10_1016_j_carbpol_2012_10_051
crossref_primary_10_1002_jps_23966
crossref_primary_10_3109_03639045_2011_558091
crossref_primary_10_1016_j_xphs_2019_10_010
crossref_primary_10_3390_ijms25052774
crossref_primary_10_1111_jphp_12145
crossref_primary_10_3109_03639045_2015_1054400
crossref_primary_10_1007_s11095_017_2254_8
crossref_primary_10_1021_acs_molpharmaceut_9b00731
crossref_primary_10_1021_acs_molpharmaceut_9b01025
crossref_primary_10_1016_j_addr_2016_03_006
crossref_primary_10_1002_jps_23957
crossref_primary_10_1208_s12249_019_1562_1
crossref_primary_10_1021_mp100013p
crossref_primary_10_3109_03639045_2013_767825
crossref_primary_10_1016_j_ijpharm_2017_07_034
crossref_primary_10_1016_j_ejps_2018_07_007
crossref_primary_10_1016_j_ijpharm_2010_08_013
crossref_primary_10_3390_pharmaceutics13071074
crossref_primary_10_1016_j_xphs_2024_05_014
crossref_primary_10_1021_jp3106716
crossref_primary_10_1021_acs_molpharmaceut_7b00492
crossref_primary_10_1021_mp9002283
crossref_primary_10_1021_mp100205g
crossref_primary_10_1016_j_ijpharm_2020_119292
crossref_primary_10_1016_j_xphs_2017_10_028
crossref_primary_10_1016_j_xphs_2023_08_021
crossref_primary_10_1002_jps_22462
crossref_primary_10_1002_jps_22583
crossref_primary_10_3390_pharmaceutics13101682
crossref_primary_10_1021_acs_molpharmaceut_1c00519
crossref_primary_10_1021_acs_molpharmaceut_5b00705
crossref_primary_10_3109_03639045_2013_828216
crossref_primary_10_1007_s11095_021_03147_0
crossref_primary_10_1016_j_xphs_2022_07_020
crossref_primary_10_1016_j_jddst_2018_05_016
crossref_primary_10_1002_aic_14979
crossref_primary_10_1021_acs_molpharmaceut_0c00467
crossref_primary_10_1021_mp1003674
crossref_primary_10_3390_pharmaceutics13111857
crossref_primary_10_1016_j_ijpharm_2021_120637
crossref_primary_10_1021_acs_molpharmaceut_5b00041
crossref_primary_10_1016_j_xphs_2016_08_017
crossref_primary_10_3390_pharmaceutics11090436
crossref_primary_10_1615_CritRevTherDrugCarrierSyst_2023039877
crossref_primary_10_1016_j_ijpharm_2011_01_035
crossref_primary_10_1016_j_colsurfb_2018_06_053
crossref_primary_10_1016_j_ijpharm_2022_121747
crossref_primary_10_1016_j_jconrel_2018_08_016
crossref_primary_10_1021_mp500660m
crossref_primary_10_3390_pharmaceutics12050433
crossref_primary_10_3390_molecules21060719
crossref_primary_10_3109_10837450_2013_846374
crossref_primary_10_1002_jps_22603
crossref_primary_10_1016_j_ejps_2017_03_027
crossref_primary_10_1208_s12249_011_9686_y
crossref_primary_10_1021_acs_molpharmaceut_8b00122
crossref_primary_10_3390_pharmaceutics12050438
crossref_primary_10_1016_j_ijpharm_2020_119878
crossref_primary_10_1021_acs_cgd_0c00073
crossref_primary_10_1016_j_ejps_2018_01_004
crossref_primary_10_1039_D2SM01189A
crossref_primary_10_1016_j_xphs_2018_11_003
crossref_primary_10_1002_jps_22204
crossref_primary_10_1007_s11095_015_1848_2
crossref_primary_10_1016_j_xphs_2017_09_030
crossref_primary_10_1016_j_ejpb_2015_07_011
crossref_primary_10_1021_mp300059z
crossref_primary_10_1016_j_jconrel_2018_11_003
crossref_primary_10_3109_03639045_2014_938080
crossref_primary_10_1080_17425247_2021_1844181
crossref_primary_10_1021_acs_molpharmaceut_5b00979
crossref_primary_10_1517_17425247_2014_911728
crossref_primary_10_1016_j_ijpharm_2015_10_015
crossref_primary_10_1002_jps_23099
crossref_primary_10_1021_mp400263d
crossref_primary_10_3390_pharmaceutics13020147
crossref_primary_10_1039_D3PM00038A
crossref_primary_10_1021_mp400712m
crossref_primary_10_1208_s12249_012_9795_2
crossref_primary_10_1021_acs_molpharmaceut_1c00419
crossref_primary_10_1021_acs_molpharmaceut_8b01261
crossref_primary_10_1021_acsami_2c12666
crossref_primary_10_1021_mp400299a
crossref_primary_10_1038_s41598_017_02676_2
crossref_primary_10_1039_C0CE00592D
crossref_primary_10_1208_s12249_022_02234_8
crossref_primary_10_1016_j_addr_2011_10_009
crossref_primary_10_1016_j_addr_2015_12_019
crossref_primary_10_1016_j_jddst_2019_01_017
crossref_primary_10_1007_s11095_019_2632_5
crossref_primary_10_1021_acs_molpharmaceut_2c00357
crossref_primary_10_1111_jphp_12183
crossref_primary_10_1002_jps_23125
crossref_primary_10_1021_acs_molpharmaceut_1c00481
crossref_primary_10_3390_ph13070147
crossref_primary_10_1007_s11095_009_9970_7
crossref_primary_10_1016_j_addr_2011_07_009
crossref_primary_10_3390_polym16020286
crossref_primary_10_1016_j_chmed_2021_12_004
crossref_primary_10_1021_acs_molpharmaceut_3c00265
crossref_primary_10_1016_j_ijpharm_2020_119086
crossref_primary_10_1016_j_xphs_2018_10_038
crossref_primary_10_4155_tde_14_101
crossref_primary_10_1016_j_jconrel_2022_09_056
crossref_primary_10_1016_j_ijpharm_2023_123440
crossref_primary_10_1021_acs_molpharmaceut_3c00020
crossref_primary_10_1016_j_ijpharm_2010_12_011
crossref_primary_10_1080_10837450_2023_2233595
crossref_primary_10_1007_s40005_017_0361_5
crossref_primary_10_1016_j_ejpb_2016_03_007
crossref_primary_10_1016_j_ejps_2023_106655
crossref_primary_10_1021_mp500412d
crossref_primary_10_2174_2667387817666230425135344
crossref_primary_10_1007_s11095_017_2265_5
crossref_primary_10_1016_j_ijpharm_2022_121532
crossref_primary_10_3109_10837450903584936
crossref_primary_10_4155_tde_14_116
crossref_primary_10_1016_j_ijpharm_2021_120964
crossref_primary_10_1016_j_micromeso_2011_12_013
crossref_primary_10_1002_jps_23353
crossref_primary_10_1016_j_ijpharm_2018_11_042
crossref_primary_10_1016_j_ijpharm_2012_12_045
crossref_primary_10_1039_D2RA07019G
crossref_primary_10_1016_j_ejps_2020_105636
crossref_primary_10_1016_j_ejps_2020_105514
crossref_primary_10_1016_j_ijpharm_2014_09_010
crossref_primary_10_1002_aic_13724
crossref_primary_10_1016_j_trac_2013_06_002
crossref_primary_10_1016_j_ejpb_2013_01_008
crossref_primary_10_1016_j_ijpharm_2010_05_033
crossref_primary_10_1016_j_ejps_2018_01_014
crossref_primary_10_1016_j_ijpharm_2012_11_001
crossref_primary_10_1021_acs_molpharmaceut_1c00141
crossref_primary_10_1021_acs_jafc_5b03953
crossref_primary_10_1021_acs_molpharmaceut_2c00892
crossref_primary_10_1016_j_ijpharm_2016_10_043
crossref_primary_10_1016_j_ijpharm_2020_119300
crossref_primary_10_3109_10837450_2014_882938
crossref_primary_10_1111_jphp_12488
crossref_primary_10_1007_s12247_012_9127_9
crossref_primary_10_1016_j_ejps_2016_11_023
crossref_primary_10_1248_bpb_b19_00642
crossref_primary_10_1007_s11095_010_0306_4
crossref_primary_10_1021_acs_molpharmaceut_8b00445
crossref_primary_10_3109_10837450_2013_795168
Cites_doi 10.1016/S0939-6411(00)00076-X
10.1002/jps.1090
10.1007/s11095-007-9331-3
10.1002/1520-6017(200008)89:8<1063::AID-JPS11>3.0.CO;2-0
10.1007/s10870-007-9283-9
10.1023/A:1012167410376
10.1021/jp036080l
10.1007/s11095-008-9721-1
10.1016/S0169-409X(01)00098-9
10.1007/s11095-004-1882-y
10.1002/jps.1041
10.1023/A:1018945117471
10.1002/jps.10205
10.1016/j.jcrysgro.2004.02.023
10.1208/pt0802029
10.1063/1.1744688
10.1002/jrs.1139
10.1002/jps.1150
10.1023/A:1022219429708
10.1021/js9601896
10.1007/s11095-007-9420-3
10.1021/JS9704801
10.1248/cpb.50.822
10.1021/js980253e
10.1023/A:1011983606606
10.1002/1520-6017(200103)90:3<371::AID-JPS12>3.0.CO;2-N
10.1002/jps.2600670609
10.1016/S0022-3093(00)00107-1
10.1023/A:1018901325842
10.1002/jps.2600680720
10.1021/js9602711
10.1021/ma062860r
10.1002/jps.2600600902
10.1248/cpb.53.1240
10.1007/s11095-006-9047-9
10.1023/A:1018960405504
10.1002/jps.10308
10.1201/9780203490396
ContentType Journal Article
Copyright Copyright © 2009 American Chemical Society
Copyright_xml – notice: Copyright © 2009 American Chemical Society
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1021/mp900050c
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Moisture-Induced Immiscibility
EISSN 1543-8392
EndPage 1505
ExternalDocumentID 10_1021_mp900050c
19634917
c326109689
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
123
4.4
53G
55A
5VS
7~N
AABXI
ABMVS
ABUCX
ACGFS
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
EJD
F5P
GNL
H~9
IH9
JG
JG~
LG6
P2P
RNS
ROL
UI2
VF5
VG9
W1F
X
---
-~X
ABJNI
ABQRX
ADHLV
AHGAQ
CGR
CUPRZ
CUY
CVF
ECM
EIF
GGK
IHE
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-a380t-59f89736dcf8910059fbf3f379c76094d58bfdfbc810c3eab3efde4b65156c653
IEDL.DBID ACS
ISSN 1543-8384
IngestDate Fri Aug 23 03:16:31 EDT 2024
Sat Sep 28 07:56:00 EDT 2024
Thu Aug 27 13:42:20 EDT 2020
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords crystallization
Solid dispersion
miscibility
amorphous
moisture
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a380t-59f89736dcf8910059fbf3f379c76094d58bfdfbc810c3eab3efde4b65156c653
PMID 19634917
PageCount 14
ParticipantIDs crossref_primary_10_1021_mp900050c
pubmed_primary_19634917
acs_journals_10_1021_mp900050c
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
VG9
W1F
ACS
AEESW
AFEFF
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2009-10-05
PublicationDateYYYYMMDD 2009-10-05
PublicationDate_xml – month: 10
  year: 2009
  text: 2009-10-05
  day: 05
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Molecular pharmaceutics
PublicationTitleAlternate Mol. Pharmaceutics
PublicationYear 2009
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References Konno H. (ref16/cit16) 2008; 25
Marsac P. J. (ref17/cit17)
Hancock B. C. (ref2/cit2) 1997; 86
Vasanthavada M. (ref18/cit18) 2005; 22
He X. R. (ref26/cit26) 2001; 90
Pikal M. J. (ref6/cit6) 1978; 67
Oberholtzer E. R. (ref5/cit5) 1979; 68
Flory P. J. (ref35/cit35) 1953
Gregorowicz J. (ref37/cit37) 2007; 40
(ref40/cit40) 2006
Wang L. A. (ref20/cit20) 2005; 53
Taylor L. S. (ref13/cit13) 2001; 90
Lu Q. (ref22/cit22) 1998; 15
Yalkowsky S. H. (ref31/cit31) 1999
Blassi P. (ref45/cit45) 2007; 8
Saleki-Gerhardt A. (ref12/cit12) 1994; 11
Marsac P. J. (ref15/cit15) 2008; 25
Andronis V. (ref9/cit9) 1997; 86
Yu L. (ref4/cit4) 2001; 48
Six K. (ref23/cit23) 2003; 20
Shamblin S. L. (ref10/cit10) 1999; 16
Yalkowsky S. H. (ref41/cit41) 2003
Liang L. (ref44/cit44) 1998; 87
Tong P. (ref42/cit42) 2001; 90
Shamblin S. L. (ref28/cit28) 1998; 87
Marsac P. J. (ref24/cit24) 2007
Chiou W. L. (ref1/cit1) 1971; 60
Hoffman J. D. (ref32/cit32) 1958; 29
Chan K. L. A. (ref25/cit25) 2004; 35
Marsac P. J. (ref33/cit33) 2009; 26
Taylor L. S. (ref19/cit19) 1997; 14
Gupta M. K. (ref39/cit39) 2003; 92
Actins A. (ref43/cit43) 2008; 38
Di Martino P. (ref30/cit30) 2004; 265
Andronis V. (ref7/cit7) 2000; 271
Zhang J. (ref38/cit38) 2000; 89
Leuner C. (ref3/cit3) 2000; 50
Ford J. L. (ref11/cit11) 1986; 61
Crowley K. J. (ref29/cit29) 2002; 91
Aso Y. (ref14/cit14) 2002; 50
Hancock B. C. (ref8/cit8) 1993; 10
Marsac P. J. (ref21/cit21) 2006; 23
Rumondor A. C. F. (ref27/cit27) 2009
Zhang J. (ref36/cit36) 2001; 90
Marcolli C. (ref34/cit34) 2004; 108
References_xml – volume: 50
  start-page: 47
  issue: 1
  year: 2000
  ident: ref3/cit3
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(00)00076-X
  contributor:
    fullname: Leuner C.
– volume: 90
  start-page: 1375
  issue: 9
  year: 2001
  ident: ref36/cit36
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.1090
  contributor:
    fullname: Zhang J.
– volume: 25
  start-page: 969
  issue: 4
  year: 2008
  ident: ref16/cit16
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-007-9331-3
  contributor:
    fullname: Konno H.
– volume: 89
  start-page: 1063
  issue: 8
  year: 2000
  ident: ref38/cit38
  publication-title: J. Pharm. Sci.
  doi: 10.1002/1520-6017(200008)89:8<1063::AID-JPS11>3.0.CO;2-0
  contributor:
    fullname: Zhang J.
– volume-title: Molecular Level Understanding of Polymer Induced Formation and Stabilization of Amorphous API
  year: 2007
  ident: ref24/cit24
  contributor:
    fullname: Marsac P. J.
– volume: 38
  start-page: 169
  issue: 3
  year: 2008
  ident: ref43/cit43
  publication-title: J. Chem. Crystallogr.
  doi: 10.1007/s10870-007-9283-9
  contributor:
    fullname: Actins A.
– volume: 14
  start-page: 1691
  issue: 12
  year: 1997
  ident: ref19/cit19
  publication-title: Pharm. Res.
  doi: 10.1023/A:1012167410376
  contributor:
    fullname: Taylor L. S.
– volume: 108
  start-page: 2216
  issue: 12
  year: 2004
  ident: ref34/cit34
  publication-title: J. Phys. Chem. A
  doi: 10.1021/jp036080l
  contributor:
    fullname: Marcolli C.
– volume: 26
  start-page: 139
  issue: 1
  year: 2009
  ident: ref33/cit33
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-008-9721-1
  contributor:
    fullname: Marsac P. J.
– volume: 48
  start-page: 27
  issue: 1
  year: 2001
  ident: ref4/cit4
  publication-title: Adv. Drug Delivery Rev.
  doi: 10.1016/S0169-409X(01)00098-9
  contributor:
    fullname: Yu L.
– volume: 22
  start-page: 440
  issue: 3
  year: 2005
  ident: ref18/cit18
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-004-1882-y
  contributor:
    fullname: Vasanthavada M.
– ident: ref17/cit17
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Marsac P. J.
– volume: 90
  start-page: 888
  issue: 7
  year: 2001
  ident: ref13/cit13
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.1041
  contributor:
    fullname: Taylor L. S.
– volume: 11
  start-page: 1166
  issue: 8
  year: 1994
  ident: ref12/cit12
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018945117471
  contributor:
    fullname: Saleki-Gerhardt A.
– volume: 91
  start-page: 2150
  issue: 10
  year: 2002
  ident: ref29/cit29
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.10205
  contributor:
    fullname: Crowley K. J.
– volume: 61
  start-page: 69
  year: 1986
  ident: ref11/cit11
  publication-title: Pharm. Acta Helv.
  contributor:
    fullname: Ford J. L.
– volume: 265
  start-page: 302
  issue: 1
  year: 2004
  ident: ref30/cit30
  publication-title: J. Cryst. Growth
  doi: 10.1016/j.jcrysgro.2004.02.023
  contributor:
    fullname: Di Martino P.
– volume: 8
  start-page: E1−E8
  issue: 2
  year: 2007
  ident: ref45/cit45
  publication-title: AAPS Pharm. Sci. Tech.
  doi: 10.1208/pt0802029
  contributor:
    fullname: Blassi P.
– volume: 29
  start-page: 1192
  issue: 5
  year: 1958
  ident: ref32/cit32
  publication-title: J. Chem. Phys.
  doi: 10.1063/1.1744688
  contributor:
    fullname: Hoffman J. D.
– volume-title: Principles of Polymer Chemistry
  year: 1953
  ident: ref35/cit35
  contributor:
    fullname: Flory P. J.
– volume: 35
  start-page: 353
  issue: 5
  year: 2004
  ident: ref25/cit25
  publication-title: J. Raman Spectrosc.
  doi: 10.1002/jrs.1139
  contributor:
    fullname: Chan K. L. A.
– volume-title: The Effects of Moisture on Pharmaceutical Amorphous Solid Dispersion Systems
  year: 2009
  ident: ref27/cit27
  contributor:
    fullname: Rumondor A. C. F.
– volume: 90
  start-page: 1991
  issue: 12
  year: 2001
  ident: ref42/cit42
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.1150
  contributor:
    fullname: Tong P.
– volume: 20
  start-page: 135
  issue: 1
  year: 2003
  ident: ref23/cit23
  publication-title: Pharm. Res.
  doi: 10.1023/A:1022219429708
  contributor:
    fullname: Six K.
– volume: 86
  start-page: 1
  issue: 1
  year: 1997
  ident: ref2/cit2
  publication-title: J. Pharm. Sci.
  doi: 10.1021/js9601896
  contributor:
    fullname: Hancock B. C.
– volume: 25
  start-page: 647
  issue: 3
  year: 2008
  ident: ref15/cit15
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-007-9420-3
  contributor:
    fullname: Marsac P. J.
– volume: 87
  start-page: 694
  issue: 6
  year: 1998
  ident: ref28/cit28
  publication-title: J. Pharm. Sci.
  doi: 10.1021/JS9704801
  contributor:
    fullname: Shamblin S. L.
– volume-title: The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals
  year: 2006
  ident: ref40/cit40
– volume: 50
  start-page: 822
  issue: 6
  year: 2002
  ident: ref14/cit14
  publication-title: Chem. Pharm. Bull.
  doi: 10.1248/cpb.50.822
  contributor:
    fullname: Aso Y.
– volume: 87
  start-page: 1496
  issue: 12
  year: 1998
  ident: ref44/cit44
  publication-title: J. Pharm. Sci.
  doi: 10.1021/js980253e
  contributor:
    fullname: Liang L.
– volume: 15
  start-page: 1202
  issue: 8
  year: 1998
  ident: ref22/cit22
  publication-title: Pharm. Res.
  doi: 10.1023/A:1011983606606
  contributor:
    fullname: Lu Q.
– volume: 90
  start-page: 371
  issue: 3
  year: 2001
  ident: ref26/cit26
  publication-title: J. Pharm. Sci.
  doi: 10.1002/1520-6017(200103)90:3<371::AID-JPS12>3.0.CO;2-N
  contributor:
    fullname: He X. R.
– volume: 67
  start-page: 767
  issue: 6
  year: 1978
  ident: ref6/cit6
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600670609
  contributor:
    fullname: Pikal M. J.
– volume: 271
  start-page: 236
  issue: 3
  year: 2000
  ident: ref7/cit7
  publication-title: J. Non -Cryst. Solids
  doi: 10.1016/S0022-3093(00)00107-1
  contributor:
    fullname: Andronis V.
– volume: 10
  start-page: 1262
  issue: 9
  year: 1993
  ident: ref8/cit8
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018901325842
  contributor:
    fullname: Hancock B. C.
– volume: 68
  start-page: 863
  issue: 7
  year: 1979
  ident: ref5/cit5
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600680720
  contributor:
    fullname: Oberholtzer E. R.
– volume: 86
  start-page: 346
  issue: 3
  year: 1997
  ident: ref9/cit9
  publication-title: J. Pharm. Sci.
  doi: 10.1021/js9602711
  contributor:
    fullname: Andronis V.
– volume: 40
  start-page: 5966
  issue: 16
  year: 2007
  ident: ref37/cit37
  publication-title: Macromolecules
  doi: 10.1021/ma062860r
  contributor:
    fullname: Gregorowicz J.
– volume: 60
  start-page: 1281
  issue: 9
  year: 1971
  ident: ref1/cit1
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600600902
  contributor:
    fullname: Chiou W. L.
– volume: 53
  start-page: 1240
  issue: 10
  year: 2005
  ident: ref20/cit20
  publication-title: Chem. Pharm. Bull.
  doi: 10.1248/cpb.53.1240
  contributor:
    fullname: Wang L. A.
– volume: 23
  start-page: 2306
  issue: 10
  year: 2006
  ident: ref21/cit21
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-006-9047-9
  contributor:
    fullname: Marsac P. J.
– volume: 16
  start-page: 1119
  issue: 7
  year: 1999
  ident: ref10/cit10
  publication-title: Pharm. Res.
  doi: 10.1023/A:1018960405504
  contributor:
    fullname: Shamblin S. L.
– volume-title: Solubility and Solubilization in Aqueous Media
  year: 1999
  ident: ref31/cit31
  contributor:
    fullname: Yalkowsky S. H.
– volume: 92
  start-page: 536
  issue: 3
  year: 2003
  ident: ref39/cit39
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.10308
  contributor:
    fullname: Gupta M. K.
– volume-title: Handbook of Aqueous Solubility Data
  year: 2003
  ident: ref41/cit41
  doi: 10.1201/9780203490396
  contributor:
    fullname: Yalkowsky S. H.
SSID ssj0024523
Score 2.4149957
Snippet The objective of this study was to investigate the phase behavior of amorphous solid dispersions composed of a hydrophobic drug and a hydrophilic polymer...
SourceID crossref
pubmed
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 1492
SubjectTerms Adsorption
Calorimetry, Differential Scanning
Crystallization
Droperidol - chemistry
Drug Delivery Systems
Drug Interactions
Humidity
Hydrophobic and Hydrophilic Interactions
Indomethacin - chemistry
Ketoprofen - chemistry
Nifedipine - chemistry
Phase Transition
Pimozide - chemistry
Povidone - chemistry
Spectrophotometry, Infrared
Water - chemistry
Title Phase Behavior of Poly(vinylpyrrolidone) Containing Amorphous Solid Dispersions in the Presence of Moisture
URI http://dx.doi.org/10.1021/mp900050c
https://www.ncbi.nlm.nih.gov/pubmed/19634917
Volume 6
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA5uvvji_TIvI6gMhRWbpZf0cezCXpTCJvhWmhsMt3a0q9B_b9J21oGiUCilaQjnpDlfcjjfB8C9iShlwvGMUHBhaA4pw3OkZTALmYRzglym650nU_fljQxHmibn7pcMfg89LVeFrqXJGmC35yqEoPHPYFoT6tmFhpuCAtggmFgb-qDvn-rQw9Kt0LMFIotgMj741zAOwX6FFWG_dO4R2BHRMej4Jdl03oWzunYq7cIO9Gsa6vwEvKvHVMCKADGBsYR-vMgfPuZRvljliZbr4XEkHqFmqCqFImB_GSvDx1kKp_o1HM41k7g-UUvhPIIKLUK_KFhiQnf4HKtZkiXiFLyOR7PBxKikFYwQE3Nt2J4knosdztQd6QpUSSWW2PWY66gdH7cJlVxSRpDJsAgpFpILi2rhdIc5Nj4DzUgN8QJAxJFDmIs8S6iLasZ8RD3X4xZXi3pot0Bb2T6ofo00KLLePRR8GbQFbjduCVYlxcZPjc5Lh9VN1NJhqc3m5V_9X4G9IgVUZP2vQXOdZOIGNFKetYuZ9Ak-BcKD
link.rule.ids 315,782,786,2769,27085,27933,27934,56747,56797
linkProvider American Chemical Society
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZS8QwEA6uPuiL961rEBEFg43pkT6KByseFHYF38rmgsXddmms0H9vklarIIhQKKVpGDJp5kun830AHHmYMS7DGA2lkMhySKE4VD7iPvaoEBRH3NY79_rR0wu9vvmiybG1MMYIbXrSLonfsgvg88nUyVt6vAPmgtCAYAuDrvotr17gpNwMIiCIEup_sgh9f9RGIK5_RKAfWNLFlNul_1izDBYb5Agva1evgBmZrYLjpKaers7goK2k0mfwGCYtKXW1Bl7NpZawoUMsYK5gko-rk_dRVo2nVWHFe0SeyVNo-apq2Qh4OcmNG_JSw769Da9Hllfcfl_TcJRBgx1h4sqXuLQdPuZmzpSFXAfPtzeDqx5qhBbQkFDvDQWxonFEQsHNGdt6VMUUUSSKeRSa_Z8IKFNCMU6xx4kcMiKVkD6zMuohDwOyAWYzY-IWgFjgkPIIx740B7P8-ZjFUSx8YZb4YbANumY80-ZF0anLgV_g9GtAt8Hhp3fSaU248VujzdpvbROzkPhm67nzV_8HYL43eHxIH-6e7nfBgksOuf8B9sDsW1HKfdDRouy6yfUBoPvK8A
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS8MwEA8-QPzi-zGfQWQoWG1MH8nH4RwTdRSm4LeyvGC4tWNxQv97k7RzDgQRCqU0DUcuyd3ler8fAOc-YozLiHo9KaRnMaQ8GqnA4wHyiRAExdzWO7e7ceeNNO8tTM71tBbGCKFNT9ol8e2qHglVIQygm-HIUVz6fBEsh1FMbbDVuOvOsPVCR-dmvALsEUyCKZLQz0-tFeJ6zgrN-ZPOrrTW_yvRBlirPEjYKFW-CRZktgXqSQlBXVzBl1lFlb6CdZjMwKmLbfBuHrWEFSziGOYKJvmguPjsZ8VgVIwtiY_IM3kJLW5VSR8BG8PcqCOfaNi1r2Gzb_HF7Tmbhv0MGh8SJq6MiUvb4XNu5s5kLHfAa-v-5a7tVYQLXg8T_8MLqSI0xpHg5o5sXapiCiscUx5HJg4UIWFKKMYJ8jmWPYalEjJglk494lGId8FSZkTcBxAJFBEeIxpIczGLo48YjakIhNnqe2ENnJgxTasFo1OXC79F6feA1sDZVEPpqATe-K3RXqm7WROzoQQmBD34q_9TsJI0W-nTQ-fxEKy6HJH7LeAILH2MJ_IYLGoxOXHz6wtiLM1z
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+Behavior+of+Poly%28vinylpyrrolidone%29+Containing+Amorphous+Solid+Dispersions+in+the+Presence+of+Moisture&rft.jtitle=Molecular+pharmaceutics&rft.au=Rumondor%2C+Alfred+C.+F&rft.au=Marsac%2C+Patrick+J&rft.au=Stanford%2C+Lindsay+A&rft.au=Taylor%2C+Lynne+S&rft.date=2009-10-05&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=6&rft.issue=5&rft.spage=1492&rft.epage=1505&rft_id=info:doi/10.1021%2Fmp900050c&rft.externalDocID=c326109689
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon